Quarterly report [Sections 13 or 15(d)]

Segment Reporting - Significant expense categories (Details)

v3.25.1
Segment Reporting - Significant expense categories (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Loss from operations $ (7,460,095) $ (3,676,651)
Net Loss: $ 7,347,903 $ 3,635,088
Other segment items description Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense
Life science | Operating segment    
Operating expenses:    
PMN310 development program costs $ 4,726,340 $ 1,549,310
Other non-employee research and development costs 277,916 224,352
Employee costs 1,443,067 581,010
Other general and administrative costs 1,012,772 1,321,979
Loss from operations 7,460,095 3,676,651
Other segment items (112,192) (41,563)
Net Loss: $ 7,347,903 $ 3,635,088